The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration

Figure 4

MSCs, injected 14 days after melanoma induction, increased plasma levels of immunosuppressive cytokines and suppressed T cell-driven antitumor immune response in melanoma-bearing animals. Significantly lower number of tumor-infiltrating CD4+T cells (a), TNF-α and IL-17-producing CD4+Th1 and Th17 cells (b, c), CD8+CTLs (d), IFN-γ and IL-17-producing CD8+CTLs (e, f), granzyme B-expressing CD8+CTLs (g), significantly lower plasma levels of antitumorigenic cytokines TNF-α and IFN-γ (h, i), and significantly higher plasma levels of immunosuppressive cytokines TGF-β and IL-10 (j, k) were noticed in B16F10+MSC^14d-treated mice compared to the B16F10+PBS^14d-treated animals. Values are presented as the ; mice/group. , .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)